China’s vitamin market remains stable across most categories, with downstream purchases primarily driven by essential demand. Market activity remains subdued, as end users adopt a wait-and-see
On January 17, 2025, CSPC Innovation Pharmaceutical Co., Ltd. released its 2024 annual performance forecast, estimating net profits of RMB 45-66 million attributable to shareholders of listed
On January 24th, 2025, Hangzhou Tigermed Consulting Co., Ltd. released its 2024 annual performance forecast, projecting net profits of RMB 380-570 million attributable to shareholders of listed
On January 27th, 2025, Nenter & Co., Inc. released its 2024 annual performance forecast, projecting a net loss of RMB 400-500 million attributable to shareholders of listed companies, representing a
On January 25, 2025, Brother Enterprises Holding Co., Ltd. released its 2024 annual performance forecast, estimating net profits of RMB 36-52 million attributable to shareholders of listed companies.
In Europe, L-Isoleucine produced by EPPEN has recently passed the EU’s quality safety assessment, eventually getting access to the European market.
This week, the European vitamin market has been rife with rumors, causing significant unrest.
In Yunnan, leading sulfuric acid manufacturers have raised their quotations, resulting in elevated cost support for Dicalcium Phosphate. Market participants are adopting a cautious wait-and-see stance